TP53 mutations and head and neck cancer prognosis
Author Information
Author(s): Jenni K Peltonen, Kirsi H Vähäkangas, Henni M Helppi, Risto Bloigu, Paavo Pääkkö, Taina Turpeenniemi-Hujanen
Primary Institution: Oulu University Hospital, University of Oulu, Finland
Hypothesis
Can specific TP53 mutations predict prognosis and response to therapy in head and neck squamous cell carcinoma patients?
Conclusion
TP53 mutations in specific DNA-binding regions are associated with poorer prognosis and response to radiation therapy in head and neck cancer patients.
Supporting Evidence
- Patients with TP53 mutations in DNA-binding regions had a 5-year survival rate of 43.5%.
- Patients with wild-type TP53 had a 5-year survival rate of 77.8%.
- TP53 mutations in L3/LSH motifs resulted in a significantly poorer response to radiation therapy.
Takeaway
This study found that certain changes in a gene called TP53 can help doctors understand how serious a patient's head and neck cancer might be and how well they might respond to treatment.
Methodology
TP53 mutations were analyzed in 46 head and neck squamous cell carcinoma patients using PCR-SSCP and sequencing.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the specific patient population.
Limitations
The study had a small sample size, which may limit the generalizability of the findings.
Participant Demographics
{"total":46,"male":31,"female":15,"age_range":"28-85"}
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website